Patents by Inventor David A. Wink
David A. Wink has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10213445Abstract: The present disclosure provides methods utilizing the diazeniumdiolate-based prodrugs for the treatment of cancer via various mechanisms and procedures. The disclosure also provides kits comprising the diazeniumdiolate-based prodrugs.Type: GrantFiled: November 6, 2015Date of Patent: February 26, 2019Assignees: Arizona Board of Regents on Behalf of the University of Arizona, a body corporate, The United States of America as Represented by the Secretary of the Department of Health and Human ServicesInventors: Katrina M. Miranda, David A. Wink, Debashree Basudhar
-
Publication number: 20170333456Abstract: The present disclosure provides methods utilizing the diazeniumdiolate-based prodrugs for the treatment of cancer via various mechanisms and procedures. The disclosure also provides kits comprising the diazeniumdiolate-based prodrugs.Type: ApplicationFiled: November 6, 2015Publication date: November 23, 2017Applicants: ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSI TY OF ARIZONA, The United States of America as Represented by the Secretary of the Department of Health and Human SInventors: Katrina M. Miranda, David A. Wink, Debashree Basudhar
-
Publication number: 20160228460Abstract: Administration of an HNO/NO? donating compound, such as Angeli's salt, increases myocardial contractility while concomitantly lowering left ventricular preload in subjects experiencing heart failure. Moreover, administration of the HNO/NO? donating compound isopropylamine (IPA)/NO (Na(CH3)2CHNHN(O)NO) surprisingly exhibited positive inotropic effects in subjects experiencing heart failure that were superior to those caused by the HNO/NO? donating compound Angeli's salt. Additionally, in contrast to the effects observed with NO· donors, administration of an HNO/NO? donor in combination with a positive inotropic agent did not impair the positive inotropic effect of the positive inotropic agent. Further, HNO/NO? exerts its positive inotropic effect independent of the adrenergic system, increasing contractility even in subjects receiving beta-antagonist therapy.Type: ApplicationFiled: April 20, 2016Publication date: August 11, 2016Inventors: David A. Wink, Martin Feelisch, David A. Kass, Nazareno Paolocci, Katrina Miranda, Jon Fukuto, Tatsuo Katori
-
Patent number: 9012647Abstract: Disclosed are nitroxide modified NSAID compounds of the formula (I) or a pharmaceutically acceptable salt or enantiomer thereof: in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, and n are defined herein and pharmaceutical compositions thereof. Further disclosed is a method of treating or preventing various disorders, such as inflammation, cancer, diabetes, a cardiovascular disorder, weight gain, polyps, and/or chronic pain, in a patient comprising administering an effective amount of a compound or pharmaceutically acceptable salt or enantiomer of formula (I). A method of imaging the compound or pharmaceutically acceptable salt or enantiomer of formula (I) in the body of the animal is also provided.Type: GrantFiled: April 5, 2012Date of Patent: April 21, 2015Assignees: The United States of America, as Represented by the Secretary, Department of Health and Human Services, Wake Forest UniversityInventors: David A. Wink, Wilmarie Flores-Santana, S. Bruce King, Murali Krishna Cherukuri, James B. Mitchell
-
Publication number: 20150004259Abstract: Administration of an HNO/NO+ donating compound, such as Angeli's salt, increases myocardial contractility while concomitantly lowering left ventricular preload in subjects experiencing heart failure. Moreover, administration of the HNO/NO? donating compound isopropylamine (IPA)/NO (Na(CH3)2CHNHN(O)NO) surprisingly exhibited positive inotropic effects in subjects experiencing heart failure that were superior to those caused by the HNO/NO? donating compound Angeli's salt. Additionally, in contrast to the effects observed with NO? donors, administration of an HNO/NO? donor in combination with a positive inotropic agent did not impair the positive inotropic effect of the positive inotropic agent. Further, HNO/NO? exerts its positive inotropic effect independent of the adrenergic system, increasing contractility even in subjects receiving beta-antagonist therapy.Type: ApplicationFiled: September 17, 2014Publication date: January 1, 2015Inventors: David A. Wink, Martin Feelisch, David A. Kass, Nazareno Paolocci, Katrina Miranda, Jon Fukuto, Tatsuo Katori
-
Patent number: 8633177Abstract: Disclosed is a compound of the formula (I) or a pharmaceutically acceptable salt thereof: (I) in which R1, R2, R3, and R4 are defined herein and pharmaceutical compositions thereof. Further provided is a method of treating various disorders, such as a disorder selected from the group consisting of a cardiovascular disorder, cancer, chronic pain, alcohol dependence, and inflammation in a patient comprising administering an effective amount of a compound or pharmaceutically acceptable salt of formula (I).Type: GrantFiled: March 18, 2011Date of Patent: January 21, 2014Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, The Arizona Board of Regents, on behalf of the University of ArizonaInventors: Katrina M. Miranda, David A. Wink, Debra J. Salmon, Debashree Basudhar, Larry K. Keefer, Joseph E. Saavedra, Daniela Andrei
-
Publication number: 20130065863Abstract: Disclosed is a compound of the formula (I) or a pharmaceutically acceptable salt thereof: (I) in which R1, R2, R3, and R4 are defined herein and pharmaceutical compositions thereof. Further provided is a method of treating various disorders, such as a disorder selected from the group consisting of a cardiovascular disorder, cancer, chronic pain, alcohol dependence, and inflammation in a patient comprising administering an effective amount of a compound or pharmaceutically acceptable salt of formula (I).Type: ApplicationFiled: March 18, 2011Publication date: March 14, 2013Applicants: The Arizona Board of Regents, on behalf of the University of Arizona, Office of Technology Transfer, NIHInventors: Katrina M. Miranda, David A. Wink, Debra J. Salmon, Debashree Basudhar, Larry K. Keefer, Joseph E. Saavedra, Daniela Andrei
-
Publication number: 20120263650Abstract: Disclosed are nitroxide modified NSAID compounds of the formula (I) or a pharmaceutically acceptable salt or enantiomer thereof: in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, and n are defined herein and pharmaceutical compositions thereof. Further disclosed is a method of treating or preventing various disorders, such as inflammation, cancer, diabetes, a cardiovascular disorder, weight gain, polyps, and/or chronic pain, in a patient comprising administering an effective amount of a compound or pharmaceutically acceptable salt or enantiomer of formula (I). A method of imaging the compound or pharmaceutically acceptable salt or enantiomer of formula (I) in the body of the animal is also provided.Type: ApplicationFiled: April 5, 2012Publication date: October 18, 2012Applicants: Wake Forest University, and Human ServicesInventors: David A. Wink, Wilmarie Flores-Santana, S. Bruce King, Murali Krishna Cherukuri, James B. Mitchell
-
Patent number: 8268890Abstract: Nitroxyl donating compounds are administered prior to the onset of ischemia for the prevention and/or reduction of ischemia/reperfusion injury in subjects at risk for ischemia. Nitroxyl donors also are administered to organs to be transplanted for the prevention and/or reduction of ischemia/reperfusion injury upon reperfusion in a recipient. Nitroxyl donors include any nitroxyl donating compound. In particular cases the nitroxyl donor is a nitroxyl-donating diazeniumdiolate, such as Angeli's salt or IPA/NO.Type: GrantFiled: December 30, 2008Date of Patent: September 18, 2012Assignees: Johns Hopkins University, The United States of America as represented by the Secretary of Health and Human Services, The Regents of the University of CaliforniaInventors: David A. Wink, Martin Feelisch, Pasquale Pagliaro, David A. Kass, Nazareno Paolocci, Katrina M. Miranda, Jon M. Fukuto
-
Publication number: 20120201907Abstract: Administration of an HNO/NO? donating compound, such as Angeli's salt, increases myocardial contractility while concomitantly lowering left ventricular preload in subjects experiencing heart failure. Moreover, administration of the HNO/NO? donating compound isopropylamine (IPA)/NO (Na(CH3)2CHNHN(O)NO) surprisingly exhibited positive inotropic effects in subjects experiencing heart failure that were superior to those caused by the HNO/NO? donating compound Angeli's salt. Additionally, in contrast to the effects observed with NO donors, administration of an HNO/NO? donor in combination with a positive inotropic agent did not impair the positive inotropic effect of the positive inotropic agent. Further, HNO/NO? exerts its positive inotropic effect independent of the adrenergic system, increasing contractility even in subjects receiving beta-antagonist therapy.Type: ApplicationFiled: April 13, 2012Publication date: August 9, 2012Applicants: The Board of Supervisors of Louisiana State University and Agricultural and Mechanical College, Johns Hopkins University, The Regents of the University of California, Government of the USA represented by the Secretary of the Department of Health and Human ServicesInventors: David A. WINK, Martin FEELISCH, David A. KASS, Nazareno PAOLOCCI, Katrina MIRANDA, Jon FUKUTO, Tatsuo KATORI
-
Publication number: 20110081427Abstract: Administration of an HNO/NO? donating compound, such as Angeli's salt, increases myocardial contractility while concomitantly lowering left ventricular preload in subjects experiencing heart failure. Moreover, administration of the HNO/NO? donating compound isopropylamine (IPA)/NO (Na(CH3)2CHNHN(O)NO) surprisingly exhibited positive inotropic effects in subjects experiencing heart failure that were superior to those caused by the HNO/NO? donating compound Angeli's salt. Additionally, in contrast to the effects observed with NO? donors, administration of an HNO/NO? donor in combination with a positive inotropic agent did not impair the positive inotropic effect of the positive inotropic agent. Further, HNO/NO? exerts its positive inotropic effect independent of the adrenergic system, increasing contractility even in subjects receiving beta-antagonist therapy.Type: ApplicationFiled: November 18, 2010Publication date: April 7, 2011Applicants: The Government of the U.S.A. as represented by the Secretary of the Dept. of Health and Human Servic, The Board of Supervisors of Louisiana State University and Agricultural and Mechanical College, The Regents of the University of California, Johns Hopkins UniversityInventors: David A. Wink, Martin Feelisch, David A. Kass, Nazareno Paolocci, Katrina Miranda, Jon Fukuto, Tatsuo Katori
-
Patent number: 7863262Abstract: Administration of an HNO/NO? donating compound, such as Angeli's salt, increases myocardial contractility while concomitantly lowering left ventricular preload in subjects experiencing heart failure. Moreover, administration of the HNO/NO? donating compound isopropylamine (IPA)/NO(Na(CH3)2CHNHN(O)NO) surprisingly exhibited positive inotropic effects in subjects experiencing heart failure that were superior to those caused by the HNO/NO? donating compound Angeli's salt. Additionally, in contrast to the effects observed with NO? donors, administration of an HNO/NO? donor in combination with a positive inotropic agent did not impair the positive inotropic effect of the positive inotropic agent. Further, HNO/NO? exerts its positive inotropic effect independent of the adrenergic system, increasing contractility even in subjects receiving beta-antagonist therapy.Type: GrantFiled: March 31, 2005Date of Patent: January 4, 2011Assignees: Johns Hopkins University, The United States of America as represented by the Department of Health and Human Services, The Regents of the University of California, The Board of Supervisors of Louisiana State University and Agriculture and Mechanical CollegeInventors: David A. Wink, Martin Feelisch, David A. Kass, Nazareno Paolocci, Katrina Miranda, Jon Fukuto, Tatsuo Katori
-
Publication number: 20090246296Abstract: Nitroxyl donating compounds are administered prior to the onset of ischemia for the prevention and/or reduction of ischemia/reperfusion injury in subjects at risk for ischemia. Nitroxyl donors also are administered to organs to be transplanted for the prevention and/or reduction of ischemia/reperfusion injury upon reperfusion in a recipient. Nitroxyl donors include any nitroxyl donating compound. In particular cases the nitroxyl donor is a nitroxyl-donating diazeniumdiolate, such as Angeli's salt or IPA/NO.Type: ApplicationFiled: December 30, 2008Publication date: October 1, 2009Inventors: David A. Wink, Martin Feelisch, Pasquale Pagliaro, David A. Kass, Nazareno Paolocci, Katrina M. Miranda, Jon M. Fukuto
-
Publication number: 20090028798Abstract: Disclosed is a method for determining the redox status of a region of interest in an animal tissue. The method includes administering a nitroxyl contrast agent to the region of interest, obtaining a magnetic resonance image of the region of interest, determining the amount of reduced nitroxyl contrast agent in the region of interest, and thereby determining the redox status of the region of interest.Type: ApplicationFiled: August 10, 2006Publication date: January 29, 2009Applicant: Government of the USA, represented by the Secretary, Dept.of Health and Human ServicesInventors: James B. Mitchell, Murali K. Cherukuri, John A. Cook, Fuminori Hyodo, Alan P. Koretsky, Ken-Ichiro Matsumoto, Sankaran Subramanian, David A. Wink
-
Patent number: 6936639Abstract: Administration of an HNO/NO? donating compound, such as Angeli's salt, increases myocardial contractility while concomitantly lowering left ventricular preload in subjects experiencing heart failure Moreover, administration of the HNO/NO? donating compound isopropylamine (IPA)/NO (Na(CH3)2CHNHN(O)NO) surprisingly exhibited positive inotropic effects in subjects experiencing heart failure that were superior to those caused by the HNO/NO? donating compound Angeli's salt.Type: GrantFiled: August 21, 2002Date of Patent: August 30, 2005Assignees: The United States of America as represented by the Secretary of the Department of Health and Human Services, The Regents of the University of California, Johns Hopkins University, The Board of Supervisors of Louisiana State University and Agricultural and Mechanical College, Louisiana State University Health Sciences CenterInventors: David A. Wink, Martin Feelisch, David A. Kass, Nazareno Paolocci, Katrina Miranda, Jon Fukuto, Tatsuo Katori
-
Publication number: 20040038947Abstract: Nitroxyl donating compounds are administered prior to the onset of ischemia for the prevention and/or reduction of ischemia/reperfusion injury in subjects at risk for ischemia. Nitroxyl donors also are administered to organs to be transplanted for the prevention and/or reduction of ischemia/reperfusion injury upon reperfusion in a recipient. Nitroxyl donors include any nitroxyl donating compound. In particular cases the nitroxyl donor is a nitroxyl-donating diazeniumdiolate, such as Angeli's salt or IPA/NO.Type: ApplicationFiled: June 16, 2003Publication date: February 26, 2004Applicants: The Gov. of the U.S. of America as represented by the Sec. of the Dept. of Health & Human Services, Johns Hopkins UniversityInventors: David A. Wink, Martin Feelisch, Pasquale Pagliaro, David A. Kass, Nazareno Paolocci, Katrina M. Miranda, Jon M. Fukuto
-
Publication number: 20040039063Abstract: Administration of an HNO/NO− donating compound, such as Angeli's salt, increases myocardial contractility while concomitantly lowering left ventricular preload in subjects experiencing heart failure Moreover, administration of the HNO/NO− donating compound isopropylamine (IPA)/NO (Na(CH3)2CHNHN(O)NO) surprisingly exhibited positive inotropic effects in subjects experiencing heart failure that were superior to those caused by the HNO/NO− donating compound Angeli's salt. Additionally, in contrast to the effects observed with NO− donors, administration of an HNO/NO− donor in combination with a positive inotropic agent did not impair the positive inotropic effect of the positive inotropic agent Further, HNO/NO− exerts its positive inotropic effect independent of the adrenergic system, increasing contractility even in subjects receiving beta-antagonist therapy.Type: ApplicationFiled: August 21, 2002Publication date: February 26, 2004Applicants: Department of Health and Human Services, National Institutes of HealthInventors: David A. Wink, Martin Feelisch, David A. Kass, Nazareno Paolocci, Katrina Miranda, Jon Fukuto, Tatsuo Katori
-
Patent number: 5840759Abstract: The present invention provides a method for sensitizing hypoxic cells in a tumor to radiation, wherein nitric oxide is delivered to target hypoxic cells through the administration of a nitric oxide-containing compound that spontaneously releases nitric oxide under physiological conditions without requiring the presence of oxygen. Also provided are methods of protecting noncancerous cells or tissues in a mammal from radiation, sensitizing cancerous cells in a mammal to chemotherapeutic agents, and protecting noncancerous cells or tissues in a mammal from chemotherapeutic agents, all by administration of the same compounds.Type: GrantFiled: March 11, 1997Date of Patent: November 24, 1998Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: James B. Mitchell, Angelo Russo, Murali C. Krishna, David A. Wink, Jr., James E. Liebmann
-
Patent number: 5837736Abstract: The present invention provides a method for sensitizing hypoxic cells in a tumor to radiation, wherein nitric oxide is delivered to target hypoxic cells through the administration of a nitric oxide-containing compound that spontaneously releases nitric oxide under physiological conditions without requiring the presence of oxygen. Also provided are methods of protecting noncancerous cells or tissues in a mammal from radiation, sensitizing cancerous cells in a mammal to chemotherapeutic agents, and protecting noncancerous cells or tissues in a mammal from chemotherapeutic agents, all by administration of the same compounds.Type: GrantFiled: March 11, 1997Date of Patent: November 17, 1998Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: James B. Mitchell, Angelo Russo, Murali C. Krishna, David A. Wink, Jr., James E. Liebmann
-
Patent number: 5814667Abstract: The present invention provides a method for sensitizing hypoxic cells in a tumor to radiation, wherein nitric oxide is delivered to target hypoxic cells through the administration of a nitric oxide-containing compound that spontaneously releases nitric oxide under physiological conditions without requiring the presence of oxygen. Also provided are methods of protecting noncancerous cells or tissues in a mammal from radiation, sensitizing cancerous cells in a mammal to chemotherapeutic agents, and protecting noncancerous cells or tissues in a mammal from chemotherapeutic agents, all by administration of the same compounds.Type: GrantFiled: March 11, 1997Date of Patent: September 29, 1998Assignee: United States of America as represented by the Department of Health and Human ServicesInventors: James B. Mitchell, Angelo Russo, Murali C. Krishna, David A. Wink, Jr., James E. Liebmann